DeutschNewstral
Article
jdsupra.com on 2020-04-10 20:40
FDA and FTC Warn Against Making Unapproved COVID-19 Claims
Related news
- FDA and FTC Warn Dietary Supplement Manufacturers Against Making Fraudulent Anti-Coronavirus Claimsjdsupra.com
- FDA, FTC Warn CBD Maker Over Product Claimsjdsupra.com
- Medical Device Claims Sent to FTC, FDAjdsupra.com
- While Not Quite a Rash of Enforcement, FDA Takes Action in 2015 Against Cosmetic Products Making Unapproved Drug Claimsjdsupra.com
- FDA Labeling Guidance: Making Structure/Function Claims for Dietary Supplementsjdsupra.com
- A Joint Crackdown from the FTC and FDA on Medical Treatment Claims from CBD Companiesjdsupra.com
- FTC Comment on FDA Guidancejdsupra.com
- FDA to Prioritize Enforcement Actions Against Unapproved Homeopathic Drugsjdsupra.com
- FDA Issues Warning Letter Regarding Unapproved Stem Cell Productsjdsupra.com
- FDA And FTC To Scrutinize Biologics Competitionjdsupra.com
- FTC Tames Lions Making “Made in USA” Claimsjdsupra.com
- FDA and FTC Joint Warning Letters Target Amazon Affiliates Making False COVID-19 Claimsjdsupra.com
- FTC backs FDA guidance intended to curtail citizen petition “shenanigans”jdsupra.com
- FDA and FTC Issue Warnings Concerning e-Cigarette Marketingjdsupra.com
- Promotional Regulation and Enforcement: FDA, FTC and State Interactionsjdsupra.com
- FDA and FTC Announce Collaboration to Support Biosimilars Marketjdsupra.com
- FDA and FTC Announce Collaboration to Promote Biosimilar Competition; FDA Issues Draft Promotional Guidancejdsupra.com
- FDA Cracks Down on Unapproved Eye Productsjdsupra.com
- FDA and FTC Join Forces to Promote Biosimilarsjdsupra.com
- FTC Settles Privacy Shield Misrepresentation Claimsjdsupra.com